Barclays Keeps Equal-Weight Rating on Amrize and Ameren
Barclays maintained equal-weight ratings on Amrize and Ameren, Dow Jones Newswires reports. The report gives no rationale or price target for either stock.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reports that Barclays kept its equal-weight rating on Amrize (AMRZ) and Ameren (AEE). Both notices were published a minute apart on October 19, 2026.
The item offers no reasoning and no price target, and points to a Benzinga ratings page for details.
why it matters
An equal-weight rating is a neutral stance, meaning the analyst sees no clear edge for these shares over the broader market. Reiterations like this usually move prices little, so most investors will treat them as routine.
tags
instruments
sources
- Amrize Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 19 October 2026 at 18:59 UTC
- Ameren Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 19 October 2026 at 18:58 UTC
- Chesapeake Utilities Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 19 October 2026 at 19:09 UTC
- Cameco Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 19 October 2026 at 19:04 UTC
- Exelon Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 19 October 2026 at 19:28 UTC
- Legence Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 19 October 2026 at 19:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗